BOEHRINGER-INGELHEIM
23.5.2019 12:02:07 CEST | Business Wire | Press release
The Angels Initiative announced today at the European Stroke Organisation Conference (ESOC) 2019 in Milan that their three-year goal to create a network of 1,500 stroke-ready centres and hospitals across Europe has been achieved.
The Angels Initiative is a unique healthcare approach to improve care for people who have just suffered a stroke (acute stroke care) across Europe and in emerging markets. It is run by Boehringer Ingelheim in partnership with the European Stroke Organisation (ESO), the World Stroke Organisation (WSO), the Stroke Alliance for Europe (SAFE) and many other national stroke societies and companies.
“Stroke is one of the leading causes of disability and death. And when a stroke strikes, every second counts to deliver optimised care as fast as possible to preserve life and minimise disability,” commented Prof. Valeria Caso, past president of the ESO. “There is a need to vastly improve the quality and speed of stroke care in Europe. I’m delighted that through the Angels Initiative, we are collectively making a real change, having already established thousands of participating clinics, and the work will keep going.”
If stroke patients are treated as quickly as possible and according to best standard of care in dedicated stroke centres, their chances of survival and a disability-free life can be improved dramatically.
The Angels Initiative aims to improve stroke care by building acute stroke networks, optimising treatment processes and sharing knowledge to set-up specialised stroke-units. The common goal is to improve care for as many people as possible who have suffered a stroke and thus save lives. Started in 2016, the Angels Initiative has now established a community of more than 2,700 stroke-centres and stroke ready hospitals in 95 countries worldwide including 37 European countries.
“This is a huge achievement for the Angels Initiative in a very short period of time. At Boehringer Ingelheim we are proud to be part of this driving force, making a change for thousands of patients,” commented Thomas Fischer, Global Head of the Angels Initiative at Boehringer Ingelheim. “We have completed training in clinics in 37 European countries, but our work does not stop here. We will continue to upskill and support new fully-functional stroke-units in Europe and emerging markets.”
As an ongoing commitment to the community, the Angels Initiative and ESO recognise clinics that are helping to drive the change for better, faster stroke care, through the ESO Angels Awards. During an award ceremony at ESOC today, 331 clinics across Europe have been recognised with ESO Angels Awards for leading the way through fully-optimised stroke care.
About the Angels Initiative
Suffering a stroke is one of the
most devastating medical emergencies that can happen to a person.
Fifteen million people worldwide suffer a stroke every year; one-third
of these people die as a consequence; another third are left permanently
disabled.1,2
Guidelines recommend that patients who have had
a stroke are treated in a specialised stroke unit by a dedicated team.
In turn, treatment should be initiated as quickly as possible after
onset of symptoms3,4
but this does not always happen.
A dedicated team of Angels consultants provide doctors, nurses and ambulance crews with the training and support they need to create and improve the treatment pathways and processes around stroke care. The Angels consultants run assessments together with the hospitals; compare existing processes with guidelines; provide training and ongoing support for the hospital staff as well as process- and quality-monitoring. Examples of these measures include checklists, which help to standardise processes and to limit unnecessary delays. In addition, the Angels Initiative offers educational tools and programmes – digital as well as analogue, support for pre- and in-hospital process optimisation and a community platform for peer-to-peer exchange and access to the world’s leading stroke specialists.
For further information on the Angels Initiative, visit: https://www.angels-initiative.com/
Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/network-1500-stroke-ready-clinics-across-europe
Intended audiences:
This press release is issued from our
Corporate Headquarters in Ingelheim, Germany and is intended to provide
information about our global business. It is directed to the
international audience outside Germany. Please be aware that information
relating to the approval status and labels of approved products may vary
from country to country, and a country-specific press release on this
topic may have been issued in the countries where we do business.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190523005260/en/
Contact:
Media Contact Boehringer Ingelheim Corporate Communications Media + PR Eva Maria Schwenk 55216 Ingelheim/Germany Tel: +49 (6132) 77-98192 Fax: +49 (6132) 72-98192 Email: press@boehringer-ingelheim.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
